ENPP1 Polypeptides for Kidney Stone Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for nephrolithiasis, or kidney stones, are often ineffective in preventing recurrent stone formation and can be poorly tolerated by patients, and there is a need for novel compositions and methods to address this condition.
Innovation Solution
Administration of soluble ENPP1 or ENPP3 polypeptides, potentially fused with moieties like IgG Fc domains or albumin to enhance half-life and reduce immunogenicity, to prevent, reverse, or reduce the formation and progression of nephrolithiasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If oral phosphate supplements and thiazide diuretics are used to reduce nephrolithiasis, then stone formation may be reduced, but patient tolerance is poor and recurrent stone formation is not prevented
Solution Approach 1:
The patent changes the molecular target parameter from conventional treatments (phosphate supplements, thiazide diuretics) to ENPP1 polypeptide administration. This parameter change results in improved patient tolerance while maintaining effectiveness in preventing recurrent stone formation, as the ENPP1 polypeptide acts on a different biological pathway without the adverse effects of conventional treatments.
2Ease of operation
If reduced protein and sodium intake and acidification of urine with citric acid are used, then non-specific treatment is provided, but effectiveness in preventing recurrent stone formation is insufficient
Solution Approach 1:
The patent extracts the specific mechanism of action from general non-specific treatments and identifies ENPP1 polypeptide as the key therapeutic agent. This extraction allows for targeted treatment that specifically addresses recurrent stone formation through ENPP1 inhibition, improving reliability while maintaining ease of administration through simple polypeptide injection.
3Ease of manufacture
If high fluid intake is used, then simple treatment is provided, but effectiveness in resolving existing stones is limited
Solution Approach 1:
The patent introduces ENPP1 polypeptide as an intermediary substance that mediates between simple administration and effective stone resolution. The polypeptide acts as a therapeutic intermediary that, when administered, specifically targets and resolves existing stones while maintaining the simplicity of the treatment protocol through straightforward injection administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of soluble ENPP1 or ENPP3 polypeptides effectively prevents, reverses, or reduces the formation and progression of nephrolithiasis, providing a more effective treatment option for kidney stone disease.
Implementation Method 1
The human ENPP (ectonucleotide pyrophosphatase) protein family consists of seven extracellular, glycosylated proteins (i.e., ENPP1, ENPP2, ENPP3, ENPP4, ENPP5, ENPP6, and ENPP7) that hydrolyze phosphodiester bonds
Data Source
AI summary
The present invention includes compositions and methods for treating and/or preventing renal and/or kidney stones in a human subject. In certain embodiments, the subject is administered certain ENPP1 polypeptides or ENPP3 polypeptides, mutants, or mutant fragments thereof.